FDA notifications. FDA approves NDA for Lexiva.
D002219:Carbamates / Q000008:administration & dosage / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004359:Drug Therapy, Combination; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D010755:Organophosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D010755:Organophosphates; D013449:Sulfonamides; C426859:fosamprenavir